Abstract 112P
Background
Colorectal liver metastasis (CLM) is classified as Resectable, Unresectable, and Borderline resectable (BR) based on Technical and Oncological categories, with recommended treatments tailored to each classification. However, there is currently no appropriate classification for instances of liver recurrence in CLM (r-CLM).
Methods
This study evaluated patients with CLM who underwent initial liver resection between 2006 and 2020 and subsequently experienced liver recurrences. We investigated the long-term outcomes and prognostic factors related to r-CLM.
Results
Out of 949 cases of initial liver resection, 650 cases experienced recurrence, and among them, 392 cases were identified as r-CLM. Early recurrence within one year (er-CLM) exhibited significantly poorer overall survival (OS) compared to instances of r-CLM recurring after one year (p < 0.0001). Nonetheless, even within the er-CLM group, resected er-CLM showed notably improved prognosis in comparison to the non-resected group (5-year OS: 48.1% vs. 0%, p < 0.0001). Multivariate analysis of er-CLM identified independent prognostic factors as the number of recurrent tumors (≥ 4) (HR, 1.95; 95% CI, 1.24-3.07; p = 0.004), tumor size (≥ 5cm) (HR, 3.77; 95% CI, 1.46-9.76; p = 0.006), and presence of extrahepatic diseases (HR, 1.71; 95% CI, 1.09-2.71; p = 0.021). Stratifying these factors for recurrence-Resectable and recurrence-BR cases resulted in a significant difference in prognosis between the two groups (59.5% vs. 26.5%, p < 0.001).
Conclusions
Even in cases of early recurrence within one year, repeat liver resection contributes to extending prognosis. Regardless of the background at the initial liver resection, the number of r-CLM, tumor size, and presence of extrahepatic diseases were identified independent prognostic factors. Tailoring appropriate treatment based on the characteristics of recurrent tumors holds the potential to enhance the prognosis for r-CLM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract